Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017132547) PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/132547 International Application No.: PCT/US2017/015403
Publication Date: 03.08.2017 International Filing Date: 27.01.2017
IPC:
C12N 15/74 (2006.01) ,A61K 35/74 (2015.01) ,A61K 39/00 (2006.01) ,A61K 48/00 (2006.01) ,C07K 14/705 (2006.01) ,C07K 5/10 (2006.01) ,C12N 15/66 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
74
Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
66
Materials from micro-organisms
74
Bacteria
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
5
Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04
containing only normal peptide links
10
Tetrapeptides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
66
General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Applicants:
ADVAXIS, INC. [US/US]; 305 College Road East Princeton, New Jersey 08540, US
Inventors:
PETIT, Robert; US
PERRY, Kyle; US
PRINCIOTTA, Michael F.; US
Agent:
SCHILLING, Stephen H.; Alston & Bird LLP 101 South Tryon Street, Suite 4000 Charlotte, North Carolina, US
CHANG, Cindy; US
SKELTON, Bryan; US
KEITH, Jason A.; US
Priority Data:
62/287,87127.01.2016US
Title (EN) PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
(FR) IMMUNOTHÉRAPIE À BASE DE VECTEURS D'ADMINISTRATION PERSONNALISÉS ET UTILISATIONS ASSOCIÉES
Abstract:
(EN) Disclosed herein is a personalized immunotherapy composition for a subject having a disease or condition, including therapeutic vaccine delivery vectors and methods of making the same comprising gene expression constructs expressing frameshift-mutation-derived peptides associated with one or more neo-epitopes encoded by nucleic acid sequences comprising at least one frameshift mutation, wherein the frameshift mutation is specific to a subject's cancer or unhealthy tissue. A delivery vector of this disclosure includes bacterial vectors; or viral vectors, or peptide vaccine vectors; or DNA vaccine vectors including Listeria bacterial vectors comprising one or more fusion proteins comprising one or more frameshift-mutation-derived peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. Disclosed are also methods of using these compositions for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection in the subject.
(FR) La présente invention concerne une composition d'immunothérapie personnalisée pour un sujet présentant une maladie ou un état pathologique, comprenant des vecteurs d'administration de vaccin thérapeutique et leurs procédés de fabrication comprenant des constructions d'expression génique exprimant des peptides dérivés d'un déphasage du cadre de lecture associés à un ou plusieurs néo-épitopes codés par des séquences d'acides nucléiques comprenant au moins un déphasage du cadre de lecture, ledit déphasage du cadre de lecture étant spécifique à un tissu cancéreux ou malade du sujet. Un vecteur d'administration selon l'invention comprend des vecteurs bactériens ; ou des vecteurs viraux, ou des vecteurs de vaccins peptidiques ; ou des vecteurs de vaccins à ADN, notamment des vecteurs bactériens à Listeria comprenant une ou plusieurs protéines hybrides comprenant un ou plusieurs peptides dérivés d'un déphasage du cadre de lecture comprenant un ou plusieurs néo-épitopes présents dans des échantillons biologiques porteurs de la maladie prélevés sur le sujet. L'invention concerne également des méthodes d'utilisation de ces compositions pour induire une réponse immunitaire contre une maladie ou un état pathologique, notamment une tumeur ou un cancer, ou une infection chez le sujet.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3012829AU2017211387SG11201806392XKR1020180100443EP3408395CN108884468
IL260804IN201817028833US20190032064